Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the treatment effect of sacubitril valsartan versus
conventional therapy for heart failure (HF) in admitted patients due to exacerbation of HF on
the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) concentrations.
Phase:
Phase 4
Details
Lead Sponsor:
WDB Clinical Research Co., Ltd.
Treatments:
Angiotensin II Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors Sacubitril and valsartan sodium hydrate drug combination Valsartan